gms | German Medical Science

69. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC)
Joint Meeting mit der Mexikanischen und Kolumbianischen Gesellschaft für Neurochirurgie

Deutsche Gesellschaft für Neurochirurgie (DGNC) e. V.

03.06. - 06.06.2018, Münster

Article

Send article

Cell transplantation therapy with human neural stem cells obtained during epilepsy surgery in an animal model of traumatic brain injury

Meeting Abstract

Search Medline for

  • Maryam Khaleghi Ghadiri - Universitätsklinikum Münster, Klinik für Neurochirurgie, Münster, Deutschland

Deutsche Gesellschaft für Neurochirurgie. 69. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), Joint Meeting mit der Mexikanischen und Kolumbianischen Gesellschaft für Neurochirurgie. Münster, 03.-06.06.2018. Düsseldorf: German Medical Science GMS Publishing House; 2018. DocV115

doi: 10.3205/18dgnc116, urn:nbn:de:0183-18dgnc1160

Published: June 18, 2018

© 2018 Khaleghi Ghadiri.
This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License. See license information at http://creativecommons.org/licenses/by/4.0/.

Outline

Text

Objective: Traumatic brain injury (TBI) is one of the main health problems worldwide and cell transplantation therapy is an area of interest in treating TBI survivors. Neural stem cells (NSCs) have been discovered in brain tissues obtained during epilepsy surgery. The effect of NSCs derived from human brain tissues obtained during epilepsy surgery cultured in PuraMatrix hydrogel (PM) was investigated on brain function after TBI in a rat brain injury model.

Methods: In in vivo study, brain injury was induced in rat brain and human NSCs sourced from epileptic neocortical tissues cultured in PM were injected into the brain lesion.

Results: Human NSCs sourced from epileptic neocortical tissues seeded in PM could survive, migrate, and differentiate into neurons and astrocytes in the vicinity of the injured neocortex. TBI rats showed a significant improvement in sensorimotor function deficits after transplantation of human NSCs compared to the control groups 28 days after TBI (P<0.05). Furthermore, transplantation of NSCs in PM significantly reduced the lesion volume (0.05 ± 0.02 vs control value of 0.74 ± 01 mm3) and enhanced the mean number of surviving cells (5.8 ± 0.67 vs control value of 1.6 ± 0.4 % BrdU positive cells; P<0.05).

Conclusion: The data suggest transplantation of NSCs in PM as a potential treatment for cell therapy in TBI. Furthermore, epilepsy surgery may serve as a method to obtain human NSCs from different brain regions. This may improve our understanding of cellular and molecular mechanisms of therapeutic cell transplantation for neurological disorders, including TBI.